Polymicrobial sepsis vaccine

The Polymicrobial sepsis vaccine is an experimental vaccine candidate currently in preclinical development by SVF Vaccines. It is designed to address polymicrobial sepsis, a life-threatening condition characterized by a dysregulated host response to infections involving multiple pathogenic microorganisms. The vaccine leverages SVF Vaccines' platform technologies, which include both DNA and mRNA vaccine modalities, to elicit a protective immune response against the diverse array of pathogens typically associated with systemic septicemia. By utilizing these genetic platforms, the vaccine aims to provide a broad-spectrum immunological defense that may be more effective than traditional single-pathogen approaches in the context of complex, multi-organism infections.